We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PolyActiva Pty Ltd, a clinical-stage Australian ophthalmology biopharmaceutical company, announced it has successfully completed its Phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant.
Orasis Pharmaceuticals announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.
Bausch Health Companies and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton Pharmaceuticals announced a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals' EM-100.....